go back

Lisocabtagene Maraleucel (Breyanzi) CAR-T Therapy

Vermont rates for HCPCS Q2054

Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $630,957 · 10th–90th $630,957$630,9570%50%100%$630,957Professionalmedian $562,341 · 10th–90th $562,341$562,3410%50%$562,341$100.0K$200.0K$500.0K$1.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$562,341.33
MVP Health Care
Setting
Professional
Modifier
Global
Typical Low
$660,693.45
Median
$660,693.45
Typical High
$660,693.45
United
Setting
Facility
Modifier
Global
Typical Low
$630,957.34
Median
$630,957.34
Typical High
$630,957.34
United
Setting
Professional
Modifier
Global
Typical Low
$61,659.50
Median
$630,957.34
Typical High
$891,250.94